Targinta plans Phase 0 clinical study

Targinta’s Board of Directors has decided to focus development of the company’s therapeutic antibodies on a so-called clinical Phase 0 study (microdosing study) in cancer patients. The purpose of the clinical Phase 0 study is to show, with a very low dose of labeled antibodies, that they target the tumor and thus validate Targinta’s proprietary […]

Xintela starts next dose level of XSTEM in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the lowest XSTEM dose level at the one-month follow-up, concluded the dose […]

Xintela proposes Thomas Eldered as new Board member

Major shareholder in Xintela AB (publ) proposes that the company’s shareholders elect Thomas Eldered as a new member of the Board at the Extra General Meeting on November 28, 2022. The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company’s major […]

Xintela completes dosing of XSTEM first dose level in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the lowest dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. […]

Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers

Xintela starts its second clinical study (Phase I/IIa) with XSTEM® for the treatment of difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. The recruitment of patients for the Phase I/IIa study for the treatment of difficult-to-heal venous leg ulcers, which is carried […]

Targinta presents positive preclinical data on the antibody-drug conjugate TARG9

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on the antibody-drug conjugate TARG9 at the 2nd Integrin-Targeted Drug Development Summit, Boston, on September 1, 2022 at 11 a.m. local time (17:00 CEST). Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected […]

Targinta obtains patent grant in Japan

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), announces that the Japanese Patent Office (JPO) has granted a patent covering treatment of tumors of the central nervous system (CNS) using antibodies targeting integrin α10β1. The patent further strengthens Targinta’s intellectual property position and coverage for drug development candidates TARG9 and TARG10. […]

Targinta engages Abzena for the production of TARG9 and TARG10

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), has signed an agreement with Abzena Ltd., the leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development and manufacturing of biologics and antibody-drug conjugates (ADCs), for initial production of the drug candidates TARG9 and TARG10 that are being developed for […]